Cargando…

MEK inhibitors enhance therapeutic response towards ATRA in NF1 associated malignant peripheral nerve sheath tumors (MPNST) in-vitro

OBJECTIVE: Neurofibromatosis type 1 (NF1) is a hereditary tumor syndrome characterized by an increased risk of malignant peripheral nerve sheath tumors (MPNST). Chemotherapy of MPNST is still insufficient. In this study, we investigated whether human tumor Schwann cells derived from NF1 associated M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fischer-Huchzermeyer, Susan, Dombrowski, Anna, Wilke, Gordon, Stahn, Verena, Streubel, Anna, Mautner, Victor Felix, Harder, Anja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5683628/ https://www.ncbi.nlm.nih.gov/pubmed/29131833 http://dx.doi.org/10.1371/journal.pone.0187700

Ejemplares similares

Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts
por: Fischer-Huchzermeyer, Susan, et al.
Publicado: (2018)

Survivin Expression and Prognostic Significance in Pediatric Malignant Peripheral Nerve Sheath Tumors (MPNST)
por: Alaggio, Rita, et al.
Publicado: (2013)

Plexiform malignant peripheral nerve sheath tumor(MPNST) in infancy and childhood--a case report.
por: Nam, E. S., et al.
Publicado: (1994)

Malignant peripheral nerve sheath tumors (MPNST) – Clinicopathological study and treatment outcome of twenty-four cases
por: Kar, Madhabananda, et al.
Publicado: (2006)

HDAC8, A Potential Therapeutic Target for the Treatment of Malignant Peripheral Nerve Sheath Tumors (MPNST)
por: Lopez, Gonzalo, et al.
Publicado: (2015)

Metastatic Malignant Peripheral Nerve Sheath Tumor (MPNST) in Neurofibromatosis Type 1: Challenges in Diagnosis and Management
por: Pulliam, Steven, et al.
Publicado: (2022)

Malignant transformation of plexiform neurofibroma to MPNST while on MEK inhibitor
por: Fasih, Samir, et al.
Publicado: (2021)

How Effective Are Noninvasive Tests for Diagnosing Malignant Peripheral Nerve Sheath Tumors in Patients with Neurofibromatosis Type 1? Diagnosing MPNST in NF1 Patients
por: Schwabe, Maria, et al.
Publicado: (2019)

Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA
por: Cortes-Ciriano, Isidro, et al.
Publicado: (2023)

MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors
por: Borcherding, Dana C., et al.
Publicado: (2023)

Epithelioid Malignant Peripheral Nerve Sheath Tumor (Epithelioid-MPNST) Presenting as Bleeding Rectal Polyp: A Case Report with Systematic Literature Review
por: Patra, Susama, et al.
Publicado: (2019)

Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016)
por: Widemann, Brigitte C., et al.
Publicado: (2019)

Impaired Pten Expression in Human Malignant Peripheral Nerve Sheath Tumours
por: Bradtmöller, Maren, et al.
Publicado: (2012)

Efficacy of MEK inhibition in a recurrent malignant peripheral nerve sheath tumor
por: Nagabushan, Sumanth, et al.
Publicado: (2021)

Combinatorial therapeutic targeting of BMP2 and MEK-ERK pathways in NF1-associated malignant peripheral nerve sheath tumors
por: Ahsan, Sidra, et al.
Publicado: (2016)

Unmasking Intra-Tumoral Heterogeneity and Clonal Evolution in NF1-MPNST
por: Moon, Chang-In, et al.
Publicado: (2020)

Oncogenic RABL6A promotes NF1-associated MPNST progression in vivo
por: Kohlmeyer, Jordan L, et al.
Publicado: (2022)

AXL Inhibition Enhances MEK Inhibitor Sensitivity in Malignant Peripheral Nerve Sheath Tumors
por: Landers, Sharon M., et al.
Publicado: (2020)

Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model
por: Linke, Christian, et al.
Publicado: (2020)

Aberrant ATRX protein expression is associated with poor overall survival in NF1-MPNST
por: Lu, Hsiang-Chih, et al.
Publicado: (2018)

NFB-01. FUNCTIONAL CHARACTERIZATION OF ATRX LOSS IN NF1-ASSOCIATED GLIOMA AND MPNST
por: Yuan, Ming, et al.
Publicado: (2020)

Sulindac derivatives inhibit cell growth and induce apoptosis in primary cells from malignant peripheral nerve sheath tumors of NF1-patients
por: Frahm, Silke, et al.
Publicado: (2004)

Concurrent inhibition of FAK/SRC and MEK overcomes MEK inhibitor resistance in Neurofibromatosis Type I related malignant peripheral nerve sheath tumors
por: Gu, Yihui, et al.
Publicado: (2022)

Correction: Aberrant ATRX protein expression is associated with poor overall survival in NF1-MPNST
por: Lu, Hsiang-Chih, et al.
Publicado: (2021)

Molecular heterogeneity in malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1
por: Thomas, Laura, et al.
Publicado: (2012)

Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study
por: Szymanski, Jeffrey J., et al.
Publicado: (2021)

Preclinical Assessment of MEK Inhibitors for Malignant Peripheral Nerve Sheath Tumors Reveals Differences in Efficacy and Adaptive Response
por: Gu, Yihui, et al.
Publicado: (2022)

FOXM1, MEK, and CDK4/6: New Targets for Malignant Peripheral Nerve Sheath Tumor Therapy
por: Voigt, Ellen, et al.
Publicado: (2023)

BCRP expression in schwannoma, plexiform neurofibroma and MPNST
por: de Vries, Maurits, et al.
Publicado: (2017)

Treatment of malignant peripheral nerve sheath tumors in pediatric NF1 disease
por: Martin, Enrico, et al.
Publicado: (2020)

Serum biomarkers for neurofibromatosis type 1 and early detection of malignant peripheral nerve-sheath tumors
por: Park, Su-Jin, et al.
Publicado: (2013)

Sensitivity of Malignant Peripheral Nerve Sheath Tumor Cells to TRAIL Is Augmented by Loss of NF1 through Modulation of MYC/MAD and Is Potentiated by Curcumin through Induction of ROS
por: Reuss, David E., et al.
Publicado: (2013)

Surgical management of peripheral nerve sheath tumours in children, with special consideration of neurofibromatoses
por: Zipfel, Julian, et al.
Publicado: (2020)

Deep genomic analysis of malignant peripheral nerve sheath tumor cell lines challenges current malignant peripheral nerve sheath tumor diagnosis
por: Magallón-Lorenz, Miriam, et al.
Publicado: (2023)

Photothermal therapy improves the efficacy of a MEK inhibitor in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors
por: Sweeney, Elizabeth E., et al.
Publicado: (2016)

Correction to: Surgical management of peripheral nerve sheath tumours in children, with special consideration of neurofibromatoses
por: Zipfel, Julian, et al.
Publicado: (2021)

Cancer Stem Cell-Like Cells Derived from Malignant Peripheral Nerve Sheath Tumors
por: Spyra, Melanie, et al.
Publicado: (2011)

Factors Within the Endoneurial Microenvironment Act to Suppress Tumorigenesis of MPNST
por: Stratton, Jo Anne, et al.
Publicado: (2018)

Chromosome 8 gain is associated with high-grade transformation in MPNST
por: Dehner, Carina, et al.
Publicado: (2021)

PRC2 loss drives MPNST metastasis and matrix remodeling
por: Brockman, Qierra R., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_re0rrvdmf2hiforvno6lj8beae